Targeted cellular therapy with natural killer cells

Hormone and Metabolic Research

Volumn 40, Issue 2, 2008, Pages 122-125

  Klingemann, H ^a   Boissel, L ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Chimeric antigen receptor; Natural killer cells; Targeted cellular immunotherapy

Indexed keywords

CHIMERIC PROTEIN; HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; CANCER CELL; CELL THERAPY; CYTOLYSIS; GENETIC ENGINEERING; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MICE; MUTANT CHIMERIC PROTEINS; NEOPLASMS; RECEPTORS, ANTIGEN;

EID: 40549095327     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1004576     Document Type: Review

References (18)

1. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural killer cell surveillance and therapy. Nat Rev Cancer 2002; 2: 850-861
2. Arai S, Klingemann HG. Natural killer cells: can they be useful as adoptive immunotherapy for cancer? Expert Opin Biol Ther 2005; 5: 163-172
3. Karre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science 1995; 267: 978-979
4. Lanier LL. Natural killer cells: from no receptors to too many. Immunity 1997; 6: 371-378
5. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999; 29: 1656-1666
6. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487-499
7. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057
8. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-658
9. Tam YK, Miyagawa B, Ho VC, Klingemann HG. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8: 281-290
10. Klingemann HG, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 1996; 2: 68-75
11. Arai S, Kindy K, Swearingen M, Meagher R, Friend P, Maki G, Martinson J, Myint H, Klingemann HG. Phase I study of adoptive immunotherapy using the cytotoxic natural killer (NK) cell line, NK-92, for treatment of advanced renal cell carcinoma and malignant melanoma. Blood 2003; 102: 693a
12. Tonn T, Becker Sesser R, Schwabe D, Seifired E. Cellular immunotherapy of malignancies using the cloncal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535
13. Moritz D, Wels W, Mattem J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994; 91: 4318-4322
14. Uherek C, Tonn T, Uherek B, Beckers, Schnierle B, Klingemann HG, Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100: 1265-1273
15. Romanski A, Uherek C, Bug G et al. Re-targeting of an NK cell line (NK-92) with specificity for CD19 efficiently kills human B-precursor leukemic cells. Blood 2004; 104: 751a
16. Mueller T, Uherek C, Maki G, Chow KU, Klingemann HG, Tonn T, Wels WS. Expression of a CD20 specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of leukemia and lymphoma cells. Cane Immunol lmmunother in press
17. Carton G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa. Blood 2002; 99: 754-758
18. Treon SP, Hansen M, Branagan AR. Polymorphisms in FcγRIIIA (CD 16) receptor expression are associated with clinical response to rituximab in Waldenstrom's Macroglobulinemia. J Clin Onc 2005; 23: 474-481